Seelos Therapeutics Announces a Strategic Device Partnership with AptarGroup, Inc.PRNewsWire • 04/06/21
5 Small-Cap Biotech Stocks Trading Under $10 With Massive Upside Potential24/7 Wall Street • 04/03/21
Seelos Therapeutics Announces Amendment of SLS-002 Agreement to Repurchase a Significant Portion of Royalties for SLS-002 (Intranasal Racemic Ketamine Program)PRNewsWire • 02/18/21
Seelos Therapeutics Announces Issuance of a Patent for Trehalose (SLS-005) in AustraliaPRNewsWire • 01/29/21
Seelos Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter's Option to Purchase Additional SharesPRNewsWire • 01/28/21
Seelos Therapeutics Receives a Notice of Allowance in Japan for SLS-005 (Trehalose)PRNewsWire • 01/22/21
Seelos Therapeutics Announces Dosing of the First Patients in a Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive DisorderPRNewsWire • 01/15/21
Seelos Therapeutics Announces Issuance of a Patent for Trehalose (SLS-005) in IsraelPRNewsWire • 12/21/20
Seelos Therapeutics Raises $10 Million In Private Placement of Senior Secured Convertible NotePRNewsWire • 12/14/20
Seelos Therapeutics to Participate in the 3rd International Conference on Sanfilippo Syndrome and Related DiseasesPRNewsWire • 11/09/20
Seelos Therapeutics Announces Closing of $7.0 Million Registered Direct OfferingPRNewsWire • 09/09/20
Seelos Therapeutics Announces Pricing of $7.0 Million Registered Direct OfferingPRNewsWire • 09/04/20
Seelos Therapeutics to Participate in the Cantor Virtual Global Healthcare ConferencePRNewsWire • 08/28/20
Seelos Therapeutics Receives European Orphan Drug Designation for SLS-005 (Trehalose) in Sanfilippo SyndromePRNewsWire • 08/25/20
Seelos Therapeutics Receives FDA May Proceed Notice to Initiate a Phase IIb/III Trial of SLS-005 in Amyotrophic Lateral SclerosisPRNewsWire • 08/10/20